Fig. 6

Gal4 morpholino allows bypassing of early developmental stages.

(A–F) Embryos resulting from an incross between Tg[ET(hsp:Gal4VP16^s1001t);UAS:Kaede] double trangenics (A,D) or from Tg[ET(hsp:Gal4VP16^s1001t);UAS:Kaede] with Tg[UAS:N^ICD-Myc] animals (B–C, E–F) were either non-injected (NI, A–B, D–E) or injected with 3 ng of Gal4 MO (C,F). Representative specimens are depicted at 3 dpf. The lower panel shows a magnification of the different specimens after DiASP treatment (D–F). (G–J) Embryos resulting from a cross between Tg[ET(hsp:Gal4VP16^s1006t)] and Tg[UAS:N^ICD-Myc] animals were either non-injected (G and magnification in H) or injected with 3 ng of Gal4 MO (I and magnification in J). Representative specimens are depicted at 6 dpf. (K–P) Embryos resulting from a cross between Tg[hspGFF53A;UAS:EGFP] double transgenic animals and either wt (K, N) or Tg[UAS:N^ICD-Myc] (L–M, O–P) animals were either non-injected (K–L, N–O) or injected with 3 ng of Gal4 MO (M, P). Representative specimens are depicted at 7 dpf. (K–M) Maximal projections of posterior lateralis afferent ganglion (dashed circles) and central projection (white arrowheads). (N–P) Maximal projections of posterior lateralis afferent nerve. (Scale bars: 150 μm for A–F, H and J; 300 μm for G and I; 100 μm for K–P).